Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns positive
Q1 FY2026 other income / expenses was $320K, compared with -$344K a year earlier. Trailing-twelve-month other income / expenses was -$2.64M.
Context
- Other income / expenses amounted to 7.4% of revenue in FY2025, up 2.0 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near $320K or moves back toward the trailing-twelve-month quarterly average of -$659.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (3.29M) USD
- Year-over-year change
- -29.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.29M) | -29.0% |
| FY2024 | 2024-12-31 | (2.55M) | +14.6% |
| FY2023 | 2023-12-31 | (2.99M) | -206.0% |
| FY2022 | 2022-12-31 | (976K) | -693.5% |
| FY2021 | 2021-12-31 | (123K) | — |
Other Income / Expenses vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 other income / expenses of -$2.64M is the 9th highest of the 11 companies compared; the peer median is $1.54M.
- Its year-over-year change of -29.9% is the 4th highest of 11, against a peer median of -67.4%.
- Other income / expenses amounts to 5.2% of revenue for FENC, versus a peer median of 28.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.06M | +10.6% | +14.6% | — | |
| LTM Mar 2026 | $7.03M | -30.0% | +11.2% | — | |
| LTM Mar 2026 | $6.34M | -47.8% | -14.5% | 37.9% | |
| LTM Mar 2026 | $4.85M | +44.2% | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $2.76M | +155.6% | — | — |
| LTM Mar 2026 | $325K | -86.9% | — | 1.0% | |
| LTM Mar 2026 | -$1.51M | -146.9% | +2.8% | 2.2% | |
| LTM Mar 2026 | -$2.06M | -113.1% | — | 18.4% | |
| LTM Mar 2026 | -$2.64M | -29.9% | — | 5.2% | |
| LTM Mar 2026 | -$5.41M | -104.4% | — | 9176.3% | |
| LTM Mar 2026 | -$69.65M | -583.2% | — | 3924.1% | |
| Peer median (excluding FENC) | $1.54M | -67.4% | +7.0% | 28.1% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 250K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.19M | 33.05M | 41.88M | 47.22M |
| Depreciation & Amortization | 16K | 149K | 287K | 800K | 103K |
| EBITDA | (17.22M) | (22.59M) | (12.36M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1471.5% | -58.2% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.74M) | (13.06M) | 2.48M | (6.35M) |
| Operating Margin | — | -1481.3% | -61.4% | 5.2% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.59M | 787K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.08M |
| Other Income / Expenses | (123K) | (976K) | (2.99M) | (2.55M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 0 | 0 | 0 | 365K | 106K |
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| EPS (Diluted) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| Weighted Avg Shares | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.